ICDM 2025

Clinical diabetes and therapeutics 1 Novel first in class agents in diabetes and metabolic disorders (cross-specialty with Korean society for the study of obesity) Chair(s): Cheol Soo Choi, Min-Seon Kim
Friday 26 September, 08:40~10:00
Room 1
(Vista 1+2, B2F)

This session explores groundbreaking first-in-class therapies targeting key metabolic pathways in diabetes and obesity. Topics include the dual roles of GLP-1 and GLP-2 in glucose regulation and gut health, novel approaches to reducing fat mass while preserving lean body mass using bimagrumab (the myostatin-activin pathway inhibitor), and the emerging debate around GIP modulation-agonism versus antagonism-as a strategy for metabolic control. Attendees will gain insight into how these innovative mechanisms are shaping the future of metabolic disease treatment.

S05-L1 Kun Ho YoonYoon, Kun-Ho Endomedical Clinic, Korea: PG-102, a bispecific GLP-1/GLP-2 receptor agonist enhancing metabolic balance and gut tolerability in type 2 diabetes

S05-L2 Chang Hee JungUniversity of Ulsan, Korea: Novel therapeutic approach for obesity with the preservation of muscle mass

S05-L3 David D'AlessioDuke University, USA: GIP agonism vs. antagonism

Panel discussion

S05-P1
Boyeon KimSoonchunhyang University, Korea
S05-P2
Ji Hye HeoHallym University, Korea
S05-P3
Yun Kyung ChoUniversity of Ulsan, Korea

Clinical diabetes and therapeutics 2 Bone and diabetes crosstalk: unraveling the interplay between metabolism, medication, and skeletal health (cross-specialty with the Korean society for bone and mineral research) Chair(s): Chan Soo Shin, Hyeong-Kyu Park
Friday 26 September, 13:30~14:50
Room 1
(Vista 1+2, B2F)

This session delves into the complex relationship between diabetes and skeletal health. Key discussions will cover the detrimental effects of diabetes on bone metabolism, the impact of antidiabetic medications-such as SGLT2 inhibitors and GLP-1 receptor agonists-on bone integrity, and the potential metabolic benefits of anti-osteoporotic agents like denosumab in reducing diabetes risk. Attendees will gain a deeper understanding of how bone and glucose metabolism intersect and what this means for integrated therapeutic strategies.

S06-L1 Yong Jun ChoiAjou University, Korea: Diabetes and bone: unveiling the detrimental factors in diabetic bone metabolism

S06-L2 Kyoung Min KimYonsei University, Korea: Impact of antidiabetic medications on bone health: focusing on SGLT2 inhibitors and GLP-1 receptor agonists

S06-L3 Kyoung Jin KimKorea University, Korea: Exploring the metabolic impact of anti-osteoporotic drugs: is denosumab linked to diabetes risk reduction?

Panel discussion

S06-P1
Se Hee MinUniversity of Ulsan, Korea
S06-P2
Jonghan ChoiKonkuk University, Korea
S06-P3
Jeongmin LeeThe Catholic University of Korea, Korea

Clinical diabetes and therapeutics 3 Facing the era of AI drived diabetes management Chair(s): Tae Keun Oh, Mi-kyung Kim
Saturday 27 September, 11:00~12:20
Room 1
(Vista 1+2, B2F)

This session explores the transformative role of artificial intelligence in modern diabetes care. Key speakers will cover AI-based decision support systems for optimizing personalized management and healthcare outcomes, fully automated insulin delivery systems using AI meal detection and size estimation, and precision medicine approaches utilizing digital twin technology for type 1 diabetes. Participants will gain comprehensive insights into how AI is revolutionizing diabetes management through intelligent algorithms, automated therapeutic interventions, and personalized treatment strategies that promise to enhance both clinical outcomes and patient quality of life.

S07-L1 Revital NimriTel-Aviv University, Israel: Optimizing personalized management and healthcare outcomes with AI-based decision support systems

S07-L2 Clara Mosquera-LopezOregon Health & Science University, USA: Enabling fully automated insulin delivery through meal detection and size estimation using artificial intelligence

S07-L3 Joonyub LeeThe Catholic University of Korea, Korea: Personalizing diabetes treatment using AI and patient-generated life-log data

Clinical diabetes and therapeutics 4 New frontiers for GLP-1: beyond glycemic and weight control (cross-specialty with the Korean Endocrine Society) Chair(s): Bong-Soo Cha, Eun Gyoung Hong
Saturday 27 September, 13:10~14:30
Room 1
(Vista 1+2, B2F)

This session explores the pleiotropic effects of GLP-1 receptor agonists beyond glycemic and weight control. Topics include mechanistic insights, roles in neurodegeneration, and benefits in obstructive sleep apnea. Building on emerging clinical evidence on tirzepatide and semaglutide in Alzheimer’s disease and OSA, the session adopts a multidisciplinary perspective, offering broader insight into GLP-1–based therapy and broadening the therapeutic landscape for diverse chronic conditions.

S08-L1 Soo LimSeoul National University, Korea: Mechanistic insights into the pleiotropic effects of GLP-1 based therapy

S08-L2 Paul EdisonImperial College London, UK: GLP-1 RA in neurodegeneration

S08-L3 Woojin LeeSeoul National University, Department of Neurology, Korea: GLP-1 RA and OSA

구분		사전등록 (~2025년 8월 20일까지)		현장등록 (2025년 9월 25일 ~ 27일)
구분		KDA회원	비회원	KDA회원	비회원
25~27일 등록	전문의(개원의, 교수, 봉직의, 전임의 포함)	KRW 280,000	KRW 350,000	KRW 370,000	KRW 450,000
25~27일 등록	전공의, 간호사, 영양사, 사회복지사, 약사, 연구원, 운동처방사, 관련분야 교수 및 기타 (군의관 및 공중보건의 포함)	KRW 180,000	KRW 230,000	KRW 250,000	KRW 270,000
One-day 등록	전문의(개원의, 교수, 봉직의, 전임의 포함)	KRW 170,000	KRW 210,000	KRW 220,000	KRW 270,000
One-day 등록	전공의, 간호사, 영양사, 사회복지사, 약사, 연구원, 운동처방사, 관련분야 교수 및 기타 (군의관 및 공중보건의 포함)	KRW 110,000	KRW 140,000	KRW 150,000	KRW 160,000
저녁 식사	전체	KRW 55,000

Program details

평점안내 (For Korean)